DRAP Issues Recall Alert for Substandard Fever Medication Batch in Pakistan

The Drug Regulatory Authority Pakistan (DRAP) has issued a recall notice for a batch of fever medication available in the market, deeming it to be of substandard quality. This regulatory body has cautioned that the consumption of this substandard product, known as Pedolil suspension, can pose grave risks to patients, potentially endangering their lives and causing potential harm to vital organs such as the liver, kidneys, or blood.

This medication, which is typically employed to alleviate fever and body aches and is formulated using paracetamol, has come under scrutiny due to concerns about its quality. Specifically, batch 167, produced by JASM Pharma Risalpur, was identified as problematic by the Federal Drug Analyst at CDL Karachi.

Also Read: Lahore Faces Alarming Surge in Contagious ‘Pink Eye’ Cases

The manufacturer has been instructed to promptly withdraw the flawed batch from the market. Pharmacists and chemists involved in distribution and pharmacy operations have been urged to inspect their stocks immediately and cease the distribution of this particular batch. Furthermore, the regulatory authority has advised that any remaining stock be isolated and returned to the supplier or manufacturer.

In an effort to safeguard the well-being of citizens, medical professionals, and pharmacists, DRAP has also directed doctors to discontinue the use of the affected Pedolil suspension batch. The pharmaceutical company has been told to halt the distribution of this particular batch without delay. In response to the recall alert, the company has taken swift action to remove the affected Pedolil suspension batch from the market.

Additionally, DRAP’s provincial teams have intensified their surveillance efforts in medicine markets to prevent the distribution and sale of any substandard products, further prioritizing the safety of the public.